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Editorial on the Research Topic
Current Challenges in Cardiovascular Molecular Diagnostics
In the last 10 years, the development of massive parallel sequencing technology, commonly referred 
to as next-generation-sequencing (NGS) technologies, carried the genetic field in a new era, open-
ing unexplored avenues in the research of inherited cardiovascular disease (1).
As any new technology, when based on solid experimental observations and on real innovation, 
primarily generates a lot of enthusiasm among researchers as well as among patients, especially 
when it reaches a broader audience through the media coverage. However, as for every technology, 
along with the promises, the technical limitations inevitably appear, prompting more questions and 
further development. The technical refinement and the need for more robust and reliable assay 
validation standards delayed the introduction of NGS in clinical practice and the development of 
consensus standard operating procedure for the incorporation of NGS in the laboratory guidelines 
as the new standard test for the molecular diagnosis of inherited cardiovascular disease.
Here, we provide a brief review of the potential new applications and current challenges associ-
ated with the widespread use of NGS and the strategies that still need to be implemented to consider 
NGS a critical and sustainable tool for the diagnosis of cardiovascular diseases, and the detection of 
all at-risk family members.
In this research topic, we tried to raise awareness about the complexity of the issues that 
cardiologists and genetic practitioners have face. In particular, here we discuss the challenges in 
cardiovascular molecular diagnostics by targeting four aspects spanning different clinical specialties 
and timeframes, from the diagnosis to the treatment of patients. The management of patients affected 
by a genetic cardiovascular disease has changed substantially over the last decade. As a result, it is 
of critical importance to developed common managing strategies among multi-disciplinary stake-
holders, and being able to synthesize the large quantity of information generated by the healthcare 
procedures, including the genetic testing laboratory, in order to provide the best care options for the 
patients and their families (2).
PatiENtS SElECtioN aNd iNdiCatioN to GENEtiC tEStiNG
In the last years, thanks to the development of the concept of precision genomic medicine, an unprec-
edented proliferation of genetics- and genomics-guided testing has been proposed.
Although a variety of testing guidelines have been indicated by the European and American 
Societies of Cardiology (AHA, ACC, ESC, and HRS), the “real world” scenario is more heterogeneous; 
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the optimal classification of individuals for molecular testing in 
inherited cardiovascular disease remains difficult (3). Genetic 
testing should be undertaken, indeed, only if considerable suspi-
cion for an underlying genetic cardiovascular disease is present 
and always proposed after a comprehensive clinical evaluation, 
including, but not limited to, a detailed family history, cardiovas-
cular work-up, and assessment for multisystem syndromes.
As we are all learning from NGS, the clinical utility of genetic 
testing is highly dependent on the pretest probability of each 
disease; common pitfalls associated with the inappropriate use 
of genetic testing, namely, poor phenotyping and inappropriate 
genetic test selection are very often able to hamper the diagnostic 
yield and the risk of encountering false-positive results.
NGS aPProaCH to adoPt
Next-generation sequencing can be applied to panels of genes, 
to the exome, namely the targeting of all coding exons, or the 
whole genome in clinical settings exome sequencing (ES) and 
genome sequencing (GS) are mainly adopted for gene discovery 
and used as clinical testing only when a clinical diagnosis cannot 
unequivocally be established. Differently, gene panels represent a 
good compromise between testing just a few genes and obtaining 
information from the exome. This approach is usually employed 
when a clinical diagnosis has been reached and does not lend 
itself to the identification of novel genes (4).
In order to fulfill the diagnostic necessities and homogenize 
the diagnostic procedures for different cardiac conditions, the 
design of custom target sequencing panels requires an in-depth 
knowledge of the specific disease and accuracy in the selection of 
the genes to analyze, according to their level of evidence.
The numbers of genes included in each panel can differ between 
laboratories. Some laboratories apply the strategy to include only 
“major genes” for which substantial literature is reported. Other 
panels include a larger gene set that includes the aforementioned 
major genes and additional “minor genes,” for which evidence is 
still accruing.
According to these considerations, it is important to highlight 
that when planning the development of a targeted gene panel, the 
main challenge is to define its main application and the targeted 
phenotypes for which the test is conceived.
VariaNt iNtErPrEtatioN
The assessment of the pathogenicity of genetic variants is of 
crit ical importance. The high variability of the human genome 
calls to exercise extreme caution to avoid the misinterpreta-
tion of the identified genetic variants. Especially important for 
clinical genetic laboratories have been the development of large 
databases of control individuals, aiming at mimicking the genetic 
behavior of variants in a general population. When a variant is 
identified in a patient, we can now analyze its frequency in the 
largest open source database, namely the Genome Aggregation 
Database, which comprises of the data from sequencing 123,136 
exomes and 15,496 genomes (http://gnomad.broadinstitute.org) 
(5). In addition to the variant frequency, evidence such as family 
studies, functional analysis, and biocomputational assessments 
need to be considered.
Deciding how to categorize and weigh each type of evidence 
is really challenging, and it is, therefore, difficult to validate 
approaches to variant assessment, particularly for variants that 
have limited evidence, usually identified by GS or ES.
This issue actually needs the collective experience of experts 
in the community to begin to build commonly validated 
approach to variant classification. Starting from the collabora-
tion of a group of experts ACMG and Association for Molecular 
Pathology in 2015 developed a framework for evidence evalua-
tion. This framework is now in revision in order to be personal-
ized according to the gene variation (6).
SUStaiNaBilitY oF GENEtiC tEStiNG  
iN tHE “rEal World”
When evaluating a genetic testing strategy, it is important to take into 
account the costs of that strategy and to determine if the increases 
in effectiveness are worth the additional costs that broader testing 
strategies incur. Genetic testing, although generally accepted by 
the medical community as an increasingly fundamental tool for 
patients’ management, remains a relatively expensive test for which, 
identifying who should bear the economic burden, remains often 
challenging. In particular, the heterogeneity of political and socio-
economical systems make genetic testing a very different experi-
ence for patients and their family in various countries across the 
globe. Too often, the economic burden of genetic testing is loaded 
onto the pockets of the patients and their families, while apart from 
the few countries with a national program to fund genetic testing as 
every other clinical test, other systems rely on third parties for the 
management of medical expenses (7). However, contrary to what 
occurred with genetic testing for cancer, the equal acknowledg-
ment of the service provided by genetic laboratories to thousands 
of cardiovascular patients has yet to be achieved.
rEMarK CoNClUSiVE
The last few decades have brought much technological advances, 
which have forever changed the landscape of clinical genetic 
testing. Despite the natural enthusiasm for those changes, much 
remains to be done for the optimal application of the massive 
parallel sequencing technology we commonly refer to as NGS. 
Although NGS represents a powerful testing tool, it can reach its 
full potential only if integrated with improved clinical diagnos-
tics, refinement of the sequencing strategy, standardized variant 
interpretation, and economic sustainability, which requires 
genetic testing to be embraced as standard clinical practice by the 
healthcare community in its entirety.
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